Haleon plc

LSE HLN.L

Haleon plc Interest Coverage Ratio for the year ending December 31, 2023: 4.96

Haleon plc Interest Coverage Ratio is 4.96 for the year ending December 31, 2023, a -32.66% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Haleon plc Interest Coverage Ratio for the year ending December 31, 2022 was 7.36, a -95.45% change year over year.
Haleon plc Interest Coverage Ratio for the year ending December 31, 2021 was 161.92, a 50.76% change year over year.
Haleon plc Interest Coverage Ratio for the year ending December 31, 2020 was 107.40, a 207.53% change year over year.
Haleon plc Interest Coverage Ratio for the year ending December 31, 2019 was 34.92.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

LSE: HLN.L

Haleon plc

CEO	Mr. Brian James McNamara
IPO Date	July 18, 2022
Location	United Kingdom
Headquarters	Building 5
Employees	25,408
Sector	Health Care
Industries Pharmaceuticals Consumer Packaged Goods

Description

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Key trends

Past 5 years